Barclays Maintains Overweight on NuVasive, Raises Price Target to $58
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Matt Miksic maintains an Overweight rating on NuVasive (NASDAQ:NUVA) and raises the price target from $56 to $58.
August 04, 2023 | 3:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays maintains an Overweight rating on NuVasive and raises the price target from $56 to $58. This could potentially lead to a positive market reaction.
The raised price target by Barclays indicates a positive outlook for NuVasive. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100